Cocrystal Pharma Inc. announced the company has selected its broad-spectrum 3CL protease inhibitor CDI-988 for development as a potential oral therapy for norovirus.
Cocrystal Pharma Inc., Merck Sharp & Dohme Corp. and MSD R&D (China) Co. Ltd. have jointly patented new cap-dependent endonuclease (CEN) (influenza virus) inhibitors that are reported to be useful for the treatment of influenza.
